Key clinical point: The COVID-19 pandemic is driving dermatologists to describe new skin findings associated with the infection and its treatment.
Major finding: The frequency of drug reactions in patients with COVID-19 remains unknown.
Study details: The authors reviewed treatments used in COVID-19 patients with the potential for skin reactions.
Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.
Martinez-Lopez A et al. J Am Acad Dermatol. 2020. doi: 10.1016/j.jaad.2020.08.006.